Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression - Rendeiro, André F.; Casano, Joseph; Vorkas, Charles Kyriakos; Singh, Harjot; Morales, Ayana; DeSimone, Robert A.; Ellsworth, Grant B.; Soave, Rosemary; Kapadia, Shashi N.; Saito, Kohta; Brown, Christopher D.; Hsu, JingMei; et al. (medRxiv, 2020)
With a rising incidence of COVID-19-associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a Translational Pathology Research COVID-19 grant to G.I., by a ISTM grant to M.S. and by the National Center for Advancing Translational Science of the National Institute of Health Under Award Number UL1TR002384. C.K.V. is supported by NIH K08 AI132739; A.M. is supported by grant KL2TR002385 of the Clinical and Translational Science Center at Weill Cornell Medical College. K.S. is supported by NIH K08 AI139360; C.D.B. is supported by NIH T32 AI07613-19 (PI: Gulick) and by the Kellen Foundation. L.G. is supported by from the Leukemia and Lymphoma Society (LLS), a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), a Rapid Response Grant from the Functional Genomics Initiative (New York, US)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Weill Cornell Medicine, IRB 20-03021645All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQuantification of immune cell populations is available as a Supplementary Table file. Hierarchical data format files with single cell data (h5ad) are available as indicated in the repository with source code for the study (https://github.com/ElementoLab/covid-flowcyto) and raw FCS files will be made available upon post-peer review publication.